ICAM1 and atherosclerosis: At 40 weeks, a more chronic stage of atherosclerosis, ICAM-1 levels remained at about 80% of control, but MOMA-2 and NFκB levels in treated animals dropped to 34% and 28% of control, that is, inhibition of these markers became similar to the inhibition of superoxide anion.